The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

One such molecule is the CD40L, which engages CD40 on dendritic and B cells of the immune system, enabling T cells to become activated as a result. Rodent studies using coreceptor blockade with ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ELDN stock, giving a Buy rating yesterday. Thomas Smith’s ...

Islet cell transplantation is used in type 1 diabetes to replace the insulin-producing beta cells that are destroyed by the ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report) and keeping the ...